Advertisement

Topics

MariMed, Inc. Reports 2018 Fourth Quarter and Year End Results; Strong Revenue and EBITDA Growth

03:30 EDT 17 Apr 2019 | BioMedReports - Blog

  • Fourth Quarter 2018: 118% Year-Over-Year Revenue Growth
  • Fiscal 2018: 95% Revenue Year-Over-Year Growth; Adjusted EBITDA up 53%
  • Strategic Investments Position MariMed for Dynamic Growth in Cannabis and Hemp CBD

NORWOOD, April 17, 2019 (GLOBE NEWSWIRE)

Read more...

Original Article: MariMed, Inc. Reports 2018 Fourth Quarter and Year End Results; Strong Revenue and EBITDA Growth

NEXT ARTICLE

More From BioPortfolio on "MariMed, Inc. Reports 2018 Fourth Quarter and Year End Results; Strong Revenue and EBITDA Growth"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...